What question did this study set out to answer?

To review the pharmacological properties, clinical efficacy, and emerging indications of non-peptide angiotensin II receptor antagonists for hypertension and heart failure.

May 1, 1997Expert Opinion on Investigational Drugs

Angiotensin II receptor antagonists - antihypertensive agents

View Full Paper

Ask AI

Bookmark

Why the study?

Are angiotensin II receptor antagonists as effective as ACE inhibitors in treating hypertension and heart failure, and do they offer a better safety profile regarding cough?

Population

Patients with hypertension, congestive heart failure, and renal diseases

Comparison

Angiotensin II receptor antagonists vs Angiotensin converting enzyme (ACE) inhibitors

Design

Review

Authors

MBMichel BurnierPreventive Cardiology HBHR BrunnerMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Member takes

Implication

Supports ARBs as cough-free alternatives to ACE inhibitors for BP lowering; leaves open impact of AT2 stimulation and combination therapy.

Key Points

To review the pharmacological properties, clinical efficacy, and emerging indications of non-peptide angiotensin II receptor antagonists for hypertension and heart failure.
Synthesized pharmacological and clinical data evaluating non-peptide AT1 receptor antagonists against angiotensin-converting enzyme (ACE) inhibitors.
Assessed emerging evidence from ongoing large-scale clinical trials (LIFE, ELITE, and RENAAL) across hypertension, heart failure, and type 2 diabetic nephropathy.
AT1 receptor antagonists demonstrate blood pressure-lowering efficacy and systemic and renal hemodynamic effects comparable to ACE inhibitors in hypertension and renal disease.
AT1 receptor antagonists show a distinct tolerability advantage over ACE inhibitors by not inducing persistent dry cough.
Key questions persist regarding the clinical impact of unblocked AT2 receptor stimulation and potential additive benefits from combining AT1 antagonists with ACE inhibitors.

Structured PICO

Are angiotensin II receptor antagonists as effective as ACE inhibitors in treating hypertension and heart failure, and do they offer a better safety profile regarding cough?

Population

Patients with hypertension, congestive heart failure, and renal diseases

Intervention

Angiotensin II receptor antagonists (AT1 receptor antagonists)

Comparator

Angiotensin converting enzyme (ACE) inhibitors

Outcome

Blood pressure lowering and systemic/renal haemodynamic propertiessurrogate

Angiotensin II receptor antagonists provide an effective alternative to ACE inhibitors for managing hypertension and heart failure, with the significant clinical advantage of not causing cough.

Cite This Study

Burnier et al. (1997) studied this question.

synapsesocial.com/papers/6a9627ffe2c87aea1dd22b5f https://doi.org/10.1517/13543784.6.5.489

View Full Paper

Ask AI

Bookmark

Implication

Supports ARBs as cough-free alternatives to ACE inhibitors for BP lowering; leaves open impact of AT2 stimulation and combination therapy.

Angiotensin II receptor antagonists - antihypertensive agents

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Angiotensin II receptor antagonists - antihypertensive agents

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider